
Renovaro Investor Relations Material
Latest events

Q3 2025
15 May, 2025

Q2 2025
19 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Renovaro Inc
Access all reports
Renovaro Inc. is a biotechnology company focused on developing advanced allogeneic cell and gene therapies. These therapies are designed to enhance immune system responses with the potential for long-term or life-long remission in some of the most challenging cancers, as well as the treatment or possible cure of serious infectious diseases, including HIV and Hepatitis B virus (HBV). The company leverages its proprietary platforms in gene and cell therapy to create therapeutic candidates aimed at hyper-stimulating the immune system to target and destroy cancer cells and virus-infected cells. Renovaro Inc. is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.
Key slides for Renovaro Inc


Investor Presentation
Renovaro Inc


Investor Presentation
Renovaro Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
RENB
Country
🇺🇸 United States